Apogee Therapeutics (APGE) Treasury Shares (2022 - 2023)

Apogee Therapeutics (APGE) has reported Treasury Shares for 5 consecutive years, with $441330.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Treasury Shares fell 63.87% year-over-year to $441330.0; the TTM figure through Mar 2026 stood at $441330.0 (down 63.87% YoY), while the FY2025 annual figure was $637594.0, down 54.97% from the prior year.
• Treasury Shares fell to $441330.0 in Q1 2026 per APGE's latest filing, from $637594.0 in the prior quarter.
• Across five years, Treasury Shares topped out at $65.1 million in Q4 2022 and bottomed at $144090.0 in Q4 2023.
• Historically, Treasury Shares has averaged $17.9 million across 5 years, with a median of $1.4 million in 2024.
• Annual changes were most pronounced in 2023 — Treasury Shares tumbled 99.78% — and 2025, when it jumped 138.3%.
• Apogee Therapeutics' Treasury Shares stood at $65.1 million in 2022, then sank by 99.78% to $144090.0 in 2023, then jumped by 85.69% to $267564.0 in 2024, then surged by 138.3% to $637594.0 in 2025, then tumbled by 30.78% to $441330.0 in 2026.
• Business Quant data shows APGE's Treasury Shares at $441330.0 in Q1 2026, $637594.0 in Q4 2025, and $831989.0 in Q3 2025.